|
1
|
Jemal A, Siegel R, Xu JQ and Ward E:
Cancer statistics, 2010. CA Cancer J Clin. 60:277–300. 2010.
View Article : Google Scholar
|
|
2
|
Zhao WG, Yu SN, Lu ZH, Ma YH, Gu YM and
Chen J: The miR-217 microRNA functions as a potential tumor
suppressor in pancreatic ductal adenocarcinoma by targeting KRAS.
Carcinogenesis. 31:1726–1733. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Yu SN, Lu ZH, Liu CZ, et al: miRNA-96
suppresses KRAS and functions as a tumor suppressor gene in
pancreatic cancer. Cancer Res. 70:6015–6025. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Torrisani J, Bournet B, du Rieu MC, et al:
Let-7 microRNA transfer in pancreatic cancer-derived cells inhibits
in vitro cell proliferation but fails to alter tumor progression.
Hum Gene Ther. 20:831–844. 2009. View Article : Google Scholar
|
|
5
|
Ji Q, Hao X, Zhang M, et al: MicroRNA
miR-34 inhibits human pancreatic cancer tumor-initiating cells.
PLoS One. 4:e68162009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Radhakrishnan P, Mohr AM, Grandgenet PM
and Hollingsworth MA: MicroRNA-200c modulates the expression of
MUC4 and MUC16 in human pancreatic cancer. The 42nd Annual Meeting
of the American Pancreatic Association Pancreas. 40:13502011.
|
|
7
|
Bhatti I, Lee A, James V, et al: Knockdown
of microRNA-21 inhibits proliferation and increases cell death by
targeting programmed cell death 4 (PDCD4) in pancreatic ductal
adenocarcinoma. J Gastrointest Surg. 15:199–208. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Song L, Huang Q, Chen K, et al: miR-218
inhibits the invasive ability of glioma cells by direct
downregulation of IKK-β. Biochem Biophys Res Commun. 402:135–140.
2010.PubMed/NCBI
|
|
9
|
Ryu JK, Hong SM, Karikari CA, Hruban RH,
Goggins MG and Maitra A: Aberrant MicroRNA-155 expression is an
early event in the multistep progression of pancreatic
adenocarcinoma. Pancreatology. 10:66–73. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Szafranska AE, Davison TS, John J, et al:
MicroRNA expression alterations are linked to tumorigenesis and
non-neoplastic processes in pancreatic ductal adenocarcinoma.
Oncogene. 26:4442–4452. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lee EJ, Gusev Y, Jiang J, et al:
Expression profiling identifies microRNA signature in pancreatic
cancer. Int J Cancer. 120:1046–1054. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bloomston M, Frankel WL, Petrocca F, et
al: MicroRNA expression patterns to differentiate pancreatic
adenocarcinoma from normal pancreas and chronic pancreatitis. JAMA.
297:1901–1908. 2007. View Article : Google Scholar
|
|
13
|
Srivastava SK, Bhardwaj A, Singh S, et al:
MicroRNA-150 directly targets MUC4 and suppresses growth and
malignant behavior of pancreatic cancer cells. Carcinogenesis.
32:1832–1839. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ohuchida K, Mizumoto K, Kayashima T, et
al: MicroRNA expression as a predictive marker for gemcitabine
response after surgical resection of pancreatic cancer. Ann Surg
Oncol. 18:2381–2387. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Nakata K, Ohuchida K, Mizumoto K, et al:
MicroRNA-10b is overexpressed in pancreatic cancer, promotes its
invasiveness, and correlates with a poor prognosis. Surgery.
150:916–922. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Liffers ST, Munding JB, Vogt M, et al:
MicroRNA-148a is down-regulated in human pancreatic ductal
adenocarcinomas and regulates cell survival by targeting CDC25B.
Lab Invest. 91:1472–1479. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hao J, Zhang SY, Zhou YQ, Liu C, Hu XG and
Shao CH: MicroRNA 421 suppresses DPC4/Smad4 in pancreatic cancer.
Biochem Biophys Res Commun. 406:552–557. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Giovannetti E, Funel N, Peters GJ, et al:
MicroRNA-21 in pancreatic cancer: correlation with clinical outcome
and pharmacologic aspects underlying its role in the modulation of
gemcitabine activity. Cancer Res. 70:4528–4538. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Luo GP, Yu XJ, Jin C, et al:
LyP-1-conjugated nanoparticles for targeting drug delivery to
lymphatic metastatic tumors. Int J Pharm. 385:150–156. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yang F, Jin C, Yang D, et al: Magnetic
functionalised carbon nanotubes as drug vehicles for cancer lymph
node metastasis treatment. Eur J Cancer. 47:1873–1882. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lee RC, Feinbaum RL and Ambros V: The
C. elegans heterochronic gene lin-4 encodes small
RNAs with antisense complementarity to lin-14. Cell.
75:843–854. 1993.
|
|
22
|
Hwang JH, Voortman J, Giovannetti E, et
al: Identification of microRNA-21 as a biomarker for
chemoresistance and clinical outcome following adjuvant therapy in
resectable pancreatic cancer. PLoS One. 5:e106302010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kim HR, Jang SE, Beik WH, Lee SH and Hwang
JH: Chemosensitivity of indole-3-carbinol via downregulation of
microRNA-21 in gemcitabine-resistant pancreatic cancer cells. Asian
Pacific Digestive Week, Oct, 2011. J Gastroen Hepatol.
26:2322011.
|
|
24
|
Massucco P, Ribero D, Sgotto E, Mellano A,
Muratore A and Capussotti L: Prognostic significance of lymph node
metastases in pancreatic head cancer treated with extended
lymphadenectomy: not just a matter of numbers. Ann Surg Oncol.
16:3323–3332. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Riediger H, Keck T, Wellner U, et al: The
lymph node ratio is the strongest prognostic factor after resection
of pancreatic cancer. J Gastrointest Surg. 13:1337–1344. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yachida S, Jones S, Bozic I, et al:
Distant metastasis occurs late during the genetic evolution of
pancreatic cancer. Nature. 467:1114–1117. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Uesugi A, Kozaki K, Tsuruta T, et al: The
tumor suppressive microRNA miR-218 targets the mTOR component
Rictor and inhibits AKT phosphorylation in oral cancer. Cancer Res.
71:5765–5778. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Tatarano S, Chiyomaru T, Kawakami K, et
al: miR-218 on the genomic loss region of chromosome 4p15.31
functions as a tumor suppressor in bladder cancer. Int J Oncol.
39:13–21. 2011.
|
|
29
|
Leite KRM, Sousa-Canavez JM, Reis ST, et
al: Change in expression of miR-let7c, miR-100, and miR-218 from
high grade localized prostate cancer to metastasis. Urol Oncol.
29:265–269. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Alajez NM, Lenarduzzi M, Ito E, et al:
MiR-218 suppresses nasopharyngeal cancer progression through
downregulation of survivin and the SLIT2-ROBO1 pathway. Cancer Res.
71:2381–2391. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Gao CP, Zhang ZY, Liu WZ, Xiao SD, Gu WQ
and Lu H: Reduced microRNA-218 expression is associated with high
nuclear factor kappa B activation in gastric cancer. Cancer.
116:41–49. 2010.PubMed/NCBI
|
|
32
|
Davidson MR, Larsen JE, Yang IA, et al:
MicroRNA-218 is deleted and downregulated in lung squamous cell
carcinoma. PLoS One. 5:e125602010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Martinez I, Gardiner AS, Board KF, Monzon
FA, Edwards RP and Khan SA: Human papillomavirus type 16 reduces
the expression of microRNA-218 in cervical carcinoma cells.
Oncogene. 27:2575–2582. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Tie J, Pan YL, Zhao LN, et al: MiR-218
inhibits invasion and metastasis of gastric cancer by targeting the
Robo1 receptor. PLoS Genet. 6:e10008792010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wu DW, Cheng YW, Wang J, Chen CY and Lee
H: Paxillin predicts survival and relapse in non-small cell lung
cancer by microRNA-218 targeting. Cancer Res. 70:10392–10401. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhou XY, Chen XJ, Hu LM, et al:
Polymorphisms involved in the miR-218-LAMB3 pathway and
susceptibility of cervical cancer, a case-control study in Chinese
women. Gynecol Oncol. 117:287–290. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Noel LS, Champion BR, Holley CL, et al:
RoBo-1, a novel member of the urokinase plasminogen activator
receptor/CD59/Ly-6/snake toxin family selectively expressed in rat
bone and growth plate cartilage. J Biol Chem. 273:3878–3883. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Ploug M and Ellis V: Structure-function
relationships in the receptor for urokinase-type plasminogen
activator. Comparison to other members of the Ly-6 family and snake
venom α-neurotoxins. FEBS Lett. 349:163–168. 1994.PubMed/NCBI
|
|
39
|
Yang L, Li Q, Wang Q, Jiang Z and Zhang L:
Silencing of miRNA-218 promotes migration and invasion of breast
cancer via Slit2-Robo1 pathway. Biomed Pharmacother. 66:535–540.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Woo S, Fish JE, Wythe JD, Bruneau BB,
Stainier DY and Srivastava D: A novel Slit-Robo-miR-218 signaling
axis regulates VEGF-mediated heart tube formation in zebrafish. The
69th Annual Meeting of the Society for Developmental
Biology/Japanese Society of Developmental Biologists. Dev Biol.
344:4332010. View Article : Google Scholar
|
